Highlights

  • Adheris Health shares declined 13.64% to AUD 0.019 on 28 April 2026, extending yearly decline to 78.8%.
  • Q3 FY26 Revenue came in at AUD 5.4 million, down 23.9% year-on-year
  • Gross Profit declined to AUD 2.1 million, with Margin at 39.7%.
  • Net cash position stood at AUD 9.4 million at quarter-end.
  • Received AUD 6.1 million holdback payment from ANZ Business sale.
  • Company continues to target cashflow break-even in Q4 FY26.

Adheris Health Limited (ASX:AHE) shares fell 13.64% to AUD 0.019 during the afternoon session on 28 April 2026, following the release of its Q3 FY26 quarterly activities report and Appendix 4C. The stock also remained 78.89% down over the past year, with the latest update reflecting a decline in key financial metrics, even as the company reported progress across its operational and strategic priorities.

Adheris Health operates in the healthcare technology segment, providing pharmacy-driven patient engagement solutions. Through its cloud-based, AI-enabled THRiV platform, the company supports pharmacies and healthcare providers in delivering personalised patient experiences and improving medication adherence. The platform is deployed across a network of more than 25,000 pharmacies in the United States, reaching a significant portion of the population.

Revenue and Profitability Reflect Year-on-Year Decline

For the quarter ended 31 March 2026, Adheris Health reported operating Revenue of AUD 5.4 million, representing a decline of 23.9% compared to AUD 7.1 million in Q3 FY25. The reduction in Revenue was attributed to lower customer renewal rates in earlier periods, reduced bookings during the first half of FY26, and smaller average deal sizes, influenced by budget pressures within the pharmaceutical sector.

Gross Profit for the quarter totalled AUD 2.1 million, down 36.7% from AUD 3.4 million in the prior corresponding period. Gross Margin also declined to 39.7%, compared to 47.7% in Q3 FY25, reflecting the impact of fixed platform costs being spread over a lower Revenue base.

The company noted that underlying product Margin remained relatively stable at 51.5%, indicating that the product mix was broadly consistent year-on-year, with the decline in reported Margin largely linked to overall Revenue levels rather than structural changes in the offering.

Cash Flow and Balance Sheet Position

Adheris Health reported a net operating cash outflow of AUD 4.6 million for the quarter, broadly in line with the previous quarter’s outflow of AUD 4.7 million. Cash receipts from customers were AUD 7.8 million, compared to AUD 8.5 million in Q2 FY26.

Staff costs were reduced to AUD 4.1 million from AUD 5.3 million in the prior quarter, including AUD 618,000 in non-recurring payments related to workforce reductions. The company indicated that the full benefits of its cost reduction program are expected to be realised by Q4 FY26.

Administrative and corporate costs also declined to AUD 1.2 million, compared to AUD 2.0 million in the previous quarter, suggesting early impacts from cost management initiatives.

Other operating cash payments totalled AUD 7.2 million, reflecting timing-related increases in abatement payments.

A notable component of the quarter’s Cash Flow was the receipt of a AUD 6.1 million holdback payment related to the sale of the company’s ANZ Business, received on 27 January 2026. This contributed to the company’s net cash position, which stood at AUD 9.4 million at the end of the quarter.

Based on its current cash balance and operating Cash Flow profile, the company reported approximately 2.02 quarters of available funding.

Technology Platform Enhancements and Operational Progress

During the quarter, Adheris Health implemented a series of upgrades to its recently launched technology platform. These enhancements included improvements in program sizing and estimation, user interface and user experience updates, and increased configurability for digital programs.

The company indicated that these upgrades are expected to support shorter sales cycles, faster implementation timelines, and lower delivery costs. Additional enhancements are planned for the coming quarter, including expanded capabilities across digital programs, improved reporting tools, and more advanced monitoring features.

These developments form part of a broader effort to enhance the scalability and efficiency of the company’s operations, aligning with its ongoing transformation initiatives.

Execution of Strategic Priorities

Adheris Health continues to progress a set of short-term priorities introduced in November 2025, aimed at improving both commercial outcomes and operational efficiency. These priorities include building a more scalable operating model, diversifying Revenue streams, focusing on higher-Margin solutions, expanding its network, and enhancing digital engagement.

As part of these initiatives, the company reported that annualised staff costs are expected to decline to approximately AUD 14.5 million from AUD 22.0 million in FY25, reflecting ongoing cost optimisation efforts.

Revenue Diversification also showed measurable progress, with non-Vaccine Revenue accounting for 82% of total Revenue year-to-date in FY26, compared to 64% in FY25. This shift reflects growth in areas such as general medicine, specialty medicine, and GLP-1 related programs.

The company also expanded its digitally connected patient population by an additional 13.5 million during the quarter, contributing to the scale of its engagement network.

While some metrics related to higher-Margin solutions and digital engagement are still under development, the company indicated that further updates will be provided in future reporting periods.

Management Commentary and Outlook

Management highlighted that the company remains in a transition phase, with ongoing efforts to reposition the Business around a more scalable and diversified model. Progress has been made in executing pipeline opportunities, including win-back contracts, despite the quarter typically representing a slower period in the pharmaceutical buying cycle.

Looking ahead, the company expects activity levels to increase as it approaches a stronger buying period later in the calendar year. Adheris Health continues to target cashflow break-even in Q4 FY26, supported by anticipated benefits from cost reduction initiatives and ongoing operational improvements.

Platform enhancements delivered during the quarter are expected to support more efficient execution and contribute to future growth potential.

What This Means for Investors?

Adheris Health’s Q3 FY26 update reflects a mixed performance, with declines in Revenue and profitability alongside ongoing operational and strategic progress. While the company reported advancements in cost management, platform capability, and Revenue Diversification, the reduction in top-line performance appears to have influenced today’s share price movement.

The receipt of the ANZ Business holdback payment and the company’s current cash position provide some Balance Sheet support, while the targeted move toward cashflow break-even in Q4 FY26 remains a key focus.

Investors may continue to monitor how effectively the company translates its strategic initiatives into improved financial performance, particularly as it enters a potentially more active period in the pharmaceutical buying cycle.